Literature DB >> 26294334

Management of Severe Insulin Resistance in Patients with Type 1 Diabetes.

Rebecca Schechter1, Sirimon Reutrakul.   

Abstract

Managing severe insulin resistance (IR) in patients with type 1 diabetes (T1DM) can be challenging for both clinicians and patients. As average weight for patients with T1DM has increased in recent decades, IR in this population has become more widespread. Currently, almost 50 % of patients with T1DM are overweight or obese. While intensive insulin therapy is associated with reduction in complications, aggressive treatment can lead to weight gain. With increasing weight, insulin can become less effective to control glycemia, resulting in higher insulin doses and hence more weight gain. Novel strategies to break this vicious cycle are needed. This review will investigate current research on insulin formulations, lifestyle modification, adjunct therapies, and surgery that may help better manage patients with T1DM and IR.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26294334     DOI: 10.1007/s11892-015-0641-2

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  93 in total

1.  Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.

Authors:  T Heise; L Nosek; S G Bøttcher; H Hastrup; H Haahr
Journal:  Diabetes Obes Metab       Date:  2012-07-10       Impact factor: 6.577

2.  New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.

Authors:  Reinhard H A Becker; Raphael Dahmen; Karin Bergmann; Anne Lehmann; Thomas Jax; Tim Heise
Journal:  Diabetes Care       Date:  2014-08-22       Impact factor: 19.112

3.  The effect of rosiglitazone on overweight subjects with type 1 diabetes.

Authors:  Suzanne M Strowig; Philip Raskin
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

4.  Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes.

Authors:  Deepti G Bulchandani; Tara Konrady; Mitchell S Hamburg
Journal:  Endocr Pract       Date:  2007 Nov-Dec       Impact factor: 3.443

5.  Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study.

Authors:  Kristen J Nadeau; Kelsey Chow; Suhyla Alam; Kara Lindquist; Sarah Campbell; Kim McFann; Georgeanna Klingensmith; Phillipe Walravens
Journal:  Pediatr Diabetes       Date:  2014-04-03       Impact factor: 4.866

6.  Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.

Authors:  Irl B Hirsch; Bruce Bode; Jean-Pierre Courreges; Patrik Dykiel; Edward Franek; Kjeld Hermansen; Allen King; Henriette Mersebach; Melanie Davies
Journal:  Diabetes Care       Date:  2012-08-28       Impact factor: 19.112

7.  Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.

Authors:  Urd Kielgast; Thure Krarup; Jens Juul Holst; Sten Madsbad
Journal:  Diabetes Care       Date:  2011-05-18       Impact factor: 19.112

8.  Outcomes of Roux-en-Y gastric bypass surgery for severely obese patients with type 1 diabetes: a case series report.

Authors:  Carlos E Mendez; Robert J Tanenberg; Walter Pories
Journal:  Diabetes Metab Syndr Obes       Date:  2010-08-10       Impact factor: 3.168

9.  Short-term administration of pegvisomant improves hepatic insulin sensitivity and reduces soleus muscle intramyocellular lipid content in young adults with type 1 diabetes.

Authors:  A Thankamony; P H Tossavainen; A Sleigh; C Acerini; D Elleri; R N Dalton; N C Jackson; A M Umpleby; R M Williams; D B Dunger
Journal:  J Clin Endocrinol Metab       Date:  2013-12-11       Impact factor: 5.958

10.  Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.

Authors:  Jiten Vora; Torsten Christensen; Azhar Rana; Steve C Bain
Journal:  Diabetes Ther       Date:  2014-08-01       Impact factor: 2.945

View more
  4 in total

Review 1.  Weight Management in Patients with Type 1 Diabetes and Obesity.

Authors:  Adham Mottalib; Megan Kasetty; Jessica Y Mar; Taha Elseaidy; Sahar Ashrafzadeh; Osama Hamdy
Journal:  Curr Diab Rep       Date:  2017-08-23       Impact factor: 4.810

2.  Translating U-500R Randomized Clinical Trial Evidence to the Practice Setting: A Diabetes Educator/Expert Prescriber Team Approach.

Authors:  Paula M Bergen; Davida F Kruger; April D Taylor; Wael E Eid; Arti Bhan; Jeffrey A Jackson
Journal:  Diabetes Educ       Date:  2017-04-21       Impact factor: 2.140

3.  Exercise Training Induced Cardioprotection with Moderate Hyperglycemia versus Sedentary Intensive Glycemic Control in Type 1 Diabetic Rats.

Authors:  Matthew W McDonald; Michelle S Dotzert; Mao Jiang; Michael R Murray; Earl G Noble; C W James Melling
Journal:  J Diabetes Res       Date:  2018-07-05       Impact factor: 4.011

Review 4.  Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report.

Authors:  Alison B Evert; Michelle Dennison; Christopher D Gardner; W Timothy Garvey; Ka Hei Karen Lau; Janice MacLeod; Joanna Mitri; Raquel F Pereira; Kelly Rawlings; Shamera Robinson; Laura Saslow; Sacha Uelmen; Patricia B Urbanski; William S Yancy
Journal:  Diabetes Care       Date:  2019-04-18       Impact factor: 19.112

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.